To all beneficiaries enrolled in a Prepaid Health Plan (PHP): for questions about benefits and services available on or after implementation, please contact your PHP.

Table of Contents

1.0 Description of the Procedure, Product, or Service ................................................................. 1
  1.1 Definitions ............................................................................................................................ 1

2.0 Eligibility Requirements ........................................................................................................... 1
  2.1 Provisions .......................................................................................................................... 1
      2.1.1 General .................................................................................................................. 1
      2.1.2 Specific ................................................................................................................ 2
  2.2 Special Provisions ............................................................................................................... 2
      2.2.1 EPSDT Special Provision: Exception to Policy Limitations for a Medicaid Beneficiary under 21 Years of Age ............................................................... 2
      2.2.2 EPSDT does not apply to NCHC beneficiaries ..................................................... 3
      2.2.3 Health Choice Special Provision for a Health Choice Beneficiary age 6 through 18 years of age ................................................................. 3

3.0 When the Procedure, Product, or Service Is Covered ............................................................ 3
  3.1 General Criteria Covered .................................................................................................... 3
  3.2 Specific Criteria Covered .................................................................................................... 4
      3.2.1 Specific criteria covered by both Medicaid and NCHC ........................................ 4
      3.2.2 Medicaid Additional Criteria Covered ................................................................... 4
      3.2.3 NCHC Additional Criteria Covered ...................................................................... 4

4.0 When the Procedure, Product, or Service Is Not Covered ..................................................... 4
  4.1 General Criteria Not Covered ............................................................................................. 4
  4.2 Specific Criteria Not Covered ............................................................................................. 4
      4.2.1 Specific Criteria Not Covered by both Medicaid and NCHC ................................ 4
      4.2.2 Medicaid and NCHC Additional Criteria Not Covered ......................................... 5
      4.2.3 Medicaid Additional Criteria Not Covered ............................................................ 5
      4.2.4 NCHC Additional Criteria Not Covered ................................................................ 5

5.0 Requirements for and Limitations on Coverage ................................................................. 5
  5.1 Prior Approval .................................................................................................................... 5
  5.2 Prior Approval Requirements ............................................................................................. 5
      5.2.1 General .................................................................................................................. 5
      5.2.2 Specific ................................................................................................................ 6

6.0 Provider(s) Eligible to Bill for the Procedure, Product, or Service ......................................... 6
  6.1 Provider Qualifications and Occupational Licensing Entity Regulations .......................... 6
  6.2 Provider Certifications ........................................................................................................ 6

7.0 Additional Requirements ....................................................................................................... 7
  7.1 Compliance ....................................................................................................................... 7

8.0 Policy Implementation and History ...................................................................................... 8
Attachment A: Claims-Related Information ................................................................. 9
A. Claim Type .................................................................................................................. 9
B. International Classification of Diseases and Related Health Problems, Tenth Revisions,
   Clinical Modification (ICD-10-CM) and Procedural Coding System (PCS) ............. 9
C. Code(s) ...................................................................................................................... 9
D. Modifiers .................................................................................................................. 10
E. Billing Units ............................................................................................................ 10
F. Place of Service ...................................................................................................... 10
G. Co-payments ......................................................................................................... 10
H. Reimbursement ..................................................................................................... 10
1.0 Description of the Procedure, Product, or Service

Engineered T cell–based antitumor immunotherapy uses gene transfer of tumor antigen-specific T-cell receptors (TCR) or synthetic chimeric antigen receptors (CAR). CAR T-Cells are prepared from the beneficiary’s peripheral blood mononuclear cells, which are obtained via a standard leukapheresis procedure. The blood is sent to the manufacturer where the mononuclear cells are enriched for T cells. The T cells are expanded in cell culture, washed, and formulated into a suspension, which then is cryopreserved. This process may take several weeks. The product is then infused into the beneficiary. This technique has shown very encouraging results in clinical trials for treatment of types of leukemias and lymphomas.

1.1 Definitions

a. Rescue Transplant - a method of replacing blood-forming stem cells that were destroyed by treatment with high doses of anticancer drugs or radiation therapy. The stem cells help the bone marrow recover and make healthy blood cells. A rescue transplant may allow more chemotherapy or radiation therapy to be given so that more cancer cells are killed. It is usually done using the patient’s own stem cells that were saved before treatment. Also called stem cell rescue.

b. United States Food & Drug Administration (U.S. FDA) - the Food and Drug Administration is responsible for protecting the public health by ensuring the safety, efficacy, and security of human and veterinary drugs, biological products, and medical devices; and by ensuring the safety of our nation's food supply, cosmetics, and products that emit radiation.

2.0 Eligibility Requirements

2.1 Provisions

2.1.1 General

(The term “General” found throughout this policy applies to all Medicaid and NCHC policies)

a. An eligible beneficiary shall be enrolled in either:
   1. the NC Medicaid Program (Medicaid is NC Medicaid program, unless context clearly indicates otherwise); or
   2. the NC Health Choice (NCHC is NC Health Choice program, unless context clearly indicates otherwise) Program on the date of service and shall meet the criteria in Section 3.0 of this policy.

b. Provider(s) shall verify each Medicaid or NCHC beneficiary’s eligibility each time a service is rendered.
c. The Medicaid beneficiary may have service restrictions due to their eligibility category that would make them ineligible for this service.

d. Following is only one of the eligibility and other requirements for participation in the NCHC Program under GS 108A-70.21(a): Children must be between the ages of 6 through 18.

2.1.2 Specific
(The term “Specific” found throughout this policy only applies to this policy)

a. Medicaid
   None Apply.

b. NCHC
   None Apply.

2.2 Special Provisions

2.2.1 EPSDT Special Provision: Exception to Policy Limitations for a Medicaid Beneficiary under 21 Years of Age

a. 42 U.S.C. § 1396d(r) [1905(r) of the Social Security Act]

   Early and Periodic Screening, Diagnostic, and Treatment (EPSDT) is a federal Medicaid requirement that requires the state Medicaid agency to cover services, products, or procedures for Medicaid beneficiary under 21 years of age if the service is medically necessary health care to correct or ameliorate a defect, physical or mental illness, or a condition [health problem] identified through a screening examination (includes any evaluation by a physician or other licensed practitioner).

   This means EPSDT covers most of the medical or remedial care a child needs to improve or maintain his or her health in the best condition possible, compensate for a health problem, prevent it from worsening, or prevent the development of additional health problems.

   Medically necessary services will be provided in the most economic mode, as long as the treatment made available is similarly efficacious to the service requested by the beneficiary’s physician, therapist, or other licensed practitioner; the determination process does not delay the delivery of the needed service; and the determination does not limit the beneficiary’s right to a free choice of providers.

   EPSDT does not require the state Medicaid agency to provide any service, product or procedure:

   1. that is unsafe, ineffective, or experimental or investigational.
   2. that is not medical in nature or not generally recognized as an accepted method of medical practice or treatment.

   Service limitations on scope, amount, duration, frequency, location of service, and other specific criteria described in clinical coverage policies may be exceeded or may not apply as long as the provider’s documentation shows that the requested service is medically necessary “to correct or ameliorate a defect, physical or mental illness, or a condition” [health problem]; that is, provider documentation shows how the service, product, or procedure meets all EPSDT criteria, including to correct or improve or maintain the
beneficiary’s health in the best condition possible, compensate for a health problem, prevent it from worsening, or prevent the development of additional health problems.

b. **EPSDT and Prior Approval Requirements**

1. If the service, product, or procedure requires prior approval, the fact that the beneficiary is under 21 years of age does **NOT** eliminate the requirement for prior approval.

2. **IMPORTANT ADDITIONAL INFORMATION** about EPSDT and prior approval is found in the *NCTracks Provider Claims and Billing Assistance Guide*, and on the EPSDT provider page. The Web addresses are specified below.

   NCTracks Provider Claims and Billing Assistance Guide: https://www.nctracks.nc.gov/content/public/providers/provider-manuals.html

   EPSDT provider page: https://medicaid.ncdhhs.gov/

2.2.2 **EPSDT does not apply to NCHC beneficiaries**

2.2.3 **Health Choice Special Provision for a Health Choice Beneficiary age 6 through 18 years of age**

NC Medicaid shall deny the claim for coverage for an NCHC beneficiary who does not meet the criteria within Section 3.0 of this policy. Only services included under the NCHC State Plan and the NC Medicaid clinical coverage policies, service definitions, or billing codes are covered for an NCHC beneficiary.

3.0 **When the Procedure, Product, or Service Is Covered**

*Note: Refer to Subsection 2.2.1 regarding EPSDT Exception to Policy Limitations for a Medicaid Beneficiary under 21 Years of Age.*

3.1 **General Criteria Covered**

Medicaid and NCHC shall cover the procedure, product, or service related to this policy when medically necessary, and:

a. the procedure, product, or service is individualized, specific, and consistent with symptoms or confirmed diagnosis of the illness or injury under treatment, and not in excess of the beneficiary’s needs;

b. the procedure, product, or service can be safely furnished, and no equally effective and more conservative or less costly treatment is available statewide; and

c. the procedure, product, or service is furnished in a manner not primarily intended for the convenience of the beneficiary, the beneficiary’s caretaker, or the provider.
3.2  Specific Criteria Covered

3.2.1  Specific criteria covered by both Medicaid and NCHC
Medicaid and NCHC shall cover CAR T-Cell Therapy when ALL of the following criteria are met:

a. the CAR T-Cell Therapy has received approval from the United States Food & Drug Administration (U.S. FDA);

b. the CAR T-Cell Therapy is administered per U.S. FDA approved guidelines regarding:
   1. indications and usage;
   2. dosage and administration;
   3. dosage forms and strengths; and
   4. warnings and precautions;

c. the CAR T-cell Therapy is administered at a certified healthcare facility that has enrolled in the therapy’s Risk Evaluation and Mitigation Strategies (REMS) and training has been given to providers on the management of cytokine release syndrome (CRS) and neurological toxicities (see Section 6.2).

3.2.2  Medicaid Additional Criteria Covered
None Apply.

3.2.3  NCHC Additional Criteria Covered
None Apply.

4.0  When the Procedure, Product, or Service Is Not Covered

Note: Refer to Subsection 2.2.1 regarding EPSDT Exception to Policy Limitations for a Medicaid Beneficiary under 21 Years of Age.

4.1  General Criteria Not Covered
Medicaid and NCHC shall not cover the procedure, product, or service related to this policy when:

a. the beneficiary does not meet the eligibility requirements listed in Section 2.0;

b. the beneficiary does not meet the criteria listed in Section 3.0;

c. the procedure, product, or service duplicates another provider’s procedure, product, or service; or

d. the procedure, product, or service is experimental, investigational, or part of a clinical trial.

4.2  Specific Criteria Not Covered

4.2.1  Specific Criteria Not Covered by both Medicaid and NCHC
Medicaid and NCHC shall not cover CAR T-Cell Therapy for ANY one of the following:

a. the CAR T-Cell Therapy has not received approval from the U.S. FDA;

b. the CAR T-Cell Therapy is being administered outside U.S. FDA guidelines regarding:
1. indications and usage;
2. dosage and administration; or
3. dosage forms and strengths;

- the CAR T-Cell Therapy is being administered at a facility that has not enrolled in that therapy’s Risk Evaluation and Mitigation Strategy (REMS);
- repeat treatment in beneficiaries who have received another CAR T-Cell Therapy previously;
- when the beneficiary’s psychosocial history limits the beneficiary’s ability to comply with pre- and post-infusion medical care; or
- when there is current beneficiary or caretaker non-compliance that would make compliance with a disciplined medical regime improbable.

4.2.2 Medicaid and NCHC Additional Criteria Not Covered
Medicaid and NCHC shall not cover concurrent rescue transplant with infusion of any CAR T-Cell Therapy as this is considered experimental.

4.2.3 Medicaid Additional Criteria Not Covered
None Apply.

4.2.4 NCHC Additional Criteria Not Covered

a. NCGS § 108A-70.21(b) “Except as otherwise provided for eligibility, fees, deductibles, copayments, and other cost sharing charges, health benefits coverage provided to children eligible under the Program shall be equivalent to coverage provided for dependents under North Carolina Medicaid Program except for the following:
   1. No services for long-term care.
   2. No nonemergency medical transportation.
   3. No EPSDT.
   4. Dental services shall be provided on a restricted basis in accordance with criteria adopted by the Department to implement this subsection.”

5.0 Requirements for and Limitations on Coverage

5.1 Prior Approval
Medicaid and NCHC shall require prior approval for CAR T-Cell Therapy. The provider shall obtain prior approval before rendering CAR T-Cell Therapy.

5.2 Prior Approval Requirements

5.2.1 General
The provider(s) shall submit to the Department of Health and Human Services (DHHS) Utilization Review Contractor the following:

a. the prior approval request; and
5.2.2 Specific
The provider(s) shall submit the following to the NC Medicaid nurse consultant:

a. Letter of medical necessity signed by the attending physician, which documents past chemotherapy regimens and dates, the clinical and social history, and indications for treatment with CAR T-Cell therapy;

b. Copy of contract between administering facility and manufacturer of the requested CAR T-Cell therapy;

c. Serologies (less than three months old) to include Human Immunodeficiency Virus (HIV) and Hepatitis panel (positive serology results may be reported that are greater than three months old);

d. All diagnostic and procedure results, including bone marrow biopsy (not more than six months old);

e. Other diagnostic tests may be requested as appropriate; and

f. Complete psychological and social evaluation to include:
   1. beneficiary’s medical compliance;
   2. beneficiary’s support network;
   3. post-treatment care plan, with identification of primary and secondary care providers; and
   4. history of mental health issues, substance use, or legal issues.

6.0 Provider(s) Eligible to Bill for the Procedure, Product, or Service
To be eligible to bill for the procedure, product, or service related to this policy, the provider(s) shall:

a. meet Medicaid or NCHC qualifications for participation;

b. have a current and signed Department of Health and Human Services (DHHS) Provider Administrative Participation Agreement; and

C. bill only for procedures, products, and services that are within the scope of their clinical practice, as defined by the appropriate licensing entity.

6.1 Provider Qualifications and Occupational Licensing Entity Regulations
None apply.

6.2 Provider Certifications
Due to the risk of cytokine release syndrome (CRS) and neurological toxicities, CAR T-Cell Therapies are only available through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS). A REMS is a program to manage known or potential serious risks associated with a drug product and is required by the U.S. Food & Drug Administration (U.S. FDA) to ensure that the benefits of the drug outweigh its risks. The U.S. FDA has required a REMS for CAR T-Cell Therapies. Each CAR T-Cell Therapy has a respective REMS Program.
The goals of the REMS are to mitigate the risks of CRS and neurological toxicities by:

a. Ensuring that hospitals and their associated clinics that dispense CAR T-Cell Therapies are specially certified and have on-site, immediate access to tocilizumab; and

b. Ensuring those who prescribe, dispense, or administer CAR T-Cell Therapies are aware of how to manage the risks of cytokine release syndrome and neurological toxicities.

**NOTE:** All hospitals and their associated clinics must be certified and enrolled in the therapy’s respective REMS to be able to infuse CAR T-Cell Therapy.

### 7.0 Additional Requirements

*Note: Refer to Subsection 2.2.1 regarding EPSDT Exception to Policy Limitations for a Medicaid Beneficiary under 21 Years of Age.*

#### 7.1 Compliance

Provider(s) shall comply with the following in effect at the time the service is rendered:

a. All applicable agreements, federal, state and local laws and regulations including the Health Insurance Portability and Accountability Act (HIPAA) and record retention requirements; and

b. All NC Medicaid’s clinical (medical) coverage policies, guidelines, policies, provider manuals, implementation updates, and bulletins published by the Centers for Medicare and Medicaid Services (CMS), DHHS, DHHS division(s) or fiscal contractor(s).
## 8.0 Policy Implementation and History

**Original Effective Date:** December 1, 2019

**History:**

<table>
<thead>
<tr>
<th>Date</th>
<th>Section or Subsection Amended</th>
<th>Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>12/01/2019</td>
<td>All Sections and Attachment(s)</td>
<td>New Clinical Coverage Policy documenting criteria for CAR-T Cell Therapy involving the administration of tisagenlecleucel (KYMRIAH) and axicabtagene ciloleucel (YESCARTA).</td>
</tr>
<tr>
<td>12/01/2019</td>
<td>Attachment A</td>
<td>Updated policy template language “Unless directed otherwise, Institutional Claims must be billed according to the National Uniform Billing Guidelines. All claims must comply with National Coding Guidelines”.</td>
</tr>
<tr>
<td>12/01/2019</td>
<td>Table of Contents</td>
<td>Updated policy template language, “To all beneficiaries enrolled in a Prepaid Health Plan (PHP): for questions about benefits and services available on or after implementation, please contact your PHP.”</td>
</tr>
<tr>
<td>10/01/2021</td>
<td>Section 1.0</td>
<td>Descriptions of specific CAR T-Cell Therapies removed.</td>
</tr>
<tr>
<td>10/01/2021</td>
<td>Section 1.1</td>
<td>Definition added for U.S. FDA.</td>
</tr>
<tr>
<td>10/01/2021</td>
<td>Section 3.2.1</td>
<td>Removed listing of specific CAR T-Cell Therapies. Added coverage statement for FDA approved CAR T-Cell Therapies when administered per FDA approved guidelines.</td>
</tr>
<tr>
<td>10/01/2021</td>
<td>Section 4.2.1</td>
<td>Removed listing of specific CAR T-Cell Therapies. Added non-coverage statement for CAR T-Cell Therapies. Sections 4.2.3 and 4.2.4 absorbed here.</td>
</tr>
<tr>
<td>10/01/2021</td>
<td>Section 4.2.2</td>
<td>Removed listing of specific CAR T-Cell Therapies.</td>
</tr>
<tr>
<td>10/01/2021</td>
<td>Section 4.2.3</td>
<td>Section removed and information moved to Section 4.2.1</td>
</tr>
<tr>
<td>10/01/2021</td>
<td>Section 4.2.4</td>
<td>Section removed and information moved to Section 4.2.1</td>
</tr>
<tr>
<td>10/01/2021</td>
<td>Section 5.2.2</td>
<td>Added “other diagnostic tests may be requested as appropriate” to specific prior approval requirements.</td>
</tr>
<tr>
<td>10/01/2021</td>
<td>Section 5.3</td>
<td>Information moved to Attachment A.</td>
</tr>
<tr>
<td>10/01/2021</td>
<td>Section 6.2</td>
<td>Removed listing of specific CAR T-Cell Therapies.</td>
</tr>
<tr>
<td>10/01/2021</td>
<td>Attachment A</td>
<td>Specific ICD-10 CM, ICD-10 PCS, and HCPCS codes removed. Revised criteria on requirements to submit 30-day patient response to therapy with claim. This is only required for KYMRIAH for ALL.</td>
</tr>
</tbody>
</table>
Attachment A: Claims-Related Information

Provider(s) shall comply with the, NCTracks Provider Claims and Billing Assistance Guide, Medicaid bulletins, fee schedules, NC Medicaid’s clinical coverage policies and any other relevant documents for specific coverage and reimbursement for Medicaid and NCHC:

A. Claim Type

Institutional (UB-04/837I)

Unless directed otherwise, Institutional Claims must be billed according to the National Uniform Billing Guidelines. All claims must comply with National Coding Guidelines.

B. International Classification of Diseases and Related Health Problems, Tenth Revisions, Clinical Modification (ICD-10-CM) and Procedural Coding System (PCS)

Provider(s) shall report the ICD-10-CM and Procedural Coding System (PCS) to the highest level of specificity that supports medical necessity. Provider(s) shall use the current ICD-10 edition and any subsequent editions in effect at the time of service. Provider(s) shall refer to the applicable edition for code description, as it is no longer documented in the policy.

a. Provider(s) shall file inpatient claims for CAR T-Cell Therapy with the product-specific ICD-10 PCS code, if one has been assigned. If a product-specific ICD-10 PCS has not been assigned, provider(s) shall file inpatient claims with the most specific available billing code.

b. Provider(s) shall include the prior authorization (PA) number on the claim.

c. Provider(s) shall attach invoice from manufacturer of CAR T-Cell Therapy.

d. If the CAR T-Cell Therapy administered is KYMRIAH (tisagenlecleucel) for B-cell precursor acute lymphoblastic leukemia (ALL), provider(s) shall attach documentation with the claim regarding 30-day beneficiary response.

C. Code(s)

Provider(s) shall report the most specific billing code that accurately and completely describes the procedure, product or service provided. Provider(s) shall use the Current Procedural Terminology (CPT), Health Care Procedure Coding System (HCPCS), and UB-04 Data Specifications Manual (for a complete listing of valid revenue codes) and any subsequent editions in effect at the time of service. Provider(s) shall refer to the applicable edition for the code description, as it is no longer documented in the policy.

If no such specific CPT or HCPCS code exists, then the provider(s) shall report the procedure, product or service using the appropriate unlisted procedure or service code.

<table>
<thead>
<tr>
<th>Revenue Code(s)</th>
<th>0636</th>
</tr>
</thead>
<tbody>
<tr>
<td>HCPCS Code(s)</td>
<td>C9399</td>
</tr>
</tbody>
</table>
a. Provider(s) shall file outpatient claims for CAR T-Cell Therapy with Revenue Code 0636 and the product-specific HCPCS code for the CAR T-Cell Therapy. If the CAR T-Cell Therapy has been approved by the U.S. FDA but has not yet been assigned a product-specific HCPCS code, the provider shall use HCPCS C9399 (UNCLASSIFIED DRUGS OR BIOLOGICALS).

b. Provider(s) shall include the prior authorization (PA) number on the claim.

c. Provider(s) shall attach invoice from manufacturer of CAR T-Cell Therapy.

d. If the CAR T-Cell Therapy administered is KYMRIAH (tisagenlecleucel) for B-cell precursor acute lymphoblastic leukemia (ALL), provider(s) shall attach documentation with the claim regarding 30-day beneficiary response.

Unlisted Procedure or Service
CPT: The provider(s) shall refer to and comply with the Instructions for Use of the CPT Codebook, Unlisted Procedure or Service, and Special Report as documented in the current CPT in effect at the time of service.

HCPCS: The provider(s) shall refer to and comply with the Instructions for Use of HCPCS National Level II codes, Unlisted Procedure or Service and Special Report as documented in the current HCPCS edition in effect at the time of service.

D. Modifiers

Provider(s) shall follow applicable modifier guidelines.

Provider(s) billing for 340B drugs shall bill the cost that is reflective of their acquisition cost.

Provider(s) shall indicate that a drug was purchased under a 340B purchasing agreement by appending the “UD” modifier on the drug detail.

E. Billing Units

Provider(s) shall report the appropriate code(s) used which determines the billing unit(s).

Providers must bill National Drug Codes (NDCs) and appropriate NDC units.

The NDC units must be reported as “UN1.”

F. Place of Service

Inpatient Hospital, Outpatient Hospital.

G. Co-payments


H. Reimbursement

Provider(s) shall bill their usual and customary charges.

For a schedule of rates, refer to: https://medicaid.ncdhhs.gov/